Warren Lee, MD
Endocrinology, Diabetes & Metabolism · Pasadena, CANPI 1942696448
Payments from drug & device makers
Across 170 payments — averaging $22.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$837
- Bayer$721
- Lilly USA, LLC$449
- Abbott$282
- Medtronic$214
- Dexcom, Inc.$200
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,64895%
- Education$1885%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 47 | $837 |
| Bayer | 31 | $721 |
| Lilly USA, LLC | 21 | $449 |
| Abbott | 14 | $282 |
| Medtronic | 3 | $214 |
| Dexcom, Inc. | 6 | $200 |
| Boehringer Ingelheim | 6 | $150 |
| Ascendis Pharma Endocrinology Inc | 6 | $148 |
| Amgen | 5 | $138 |
| Dermavant Sciences, Inc. | 5 | $107 |
| GSK | 3 | $80 |
| AstraZeneca | 3 | $78 |
| Xeris Pharmaceuticals, Inc. | 3 | $61 |
| BETA Bionics, Inc. | 3 | $59 |
| Tandem Diabetes Care, Inc. | 2 | $46 |
| Novartis | 2 | $45 |
| Insulet Corporation | 2 | $37 |
| Rhythm Pharmaceuticals, Inc. | 1 | $27 |
| Organon | 1 | $25 |
| Sequel Med Tech, LLC | 1 | $25 |
| IBSA Pharma Inc. | 1 | $23 |
| AbbVie | 1 | $22 |
| Zealand Pharma US, Inc. | 1 | $22 |
| Corcept Therapeutics | 1 | $21 |
| Madrigal Pharmaceuticals | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Micra$152
How this compares
$3,836 in reported general payments places this provider in the 60th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 359 | $454,314 |
| OzempicSemaglutide | 352 | $362,133 |
| JanuviaSitagliptin Phosphate | 135 | $158,186 |
| TrulicityDulaglutide | 102 | $121,370 |
| ProliaDenosumab | 60 | $102,978 |
| MounjaroTirzepatide | 53 | $74,022 |
| FarxigaDapagliflozin Propanediol | 39 | $42,031 |
| EliquisApixaban | 35 | $27,850 |
| KerendiaFinerenone | 31 | $25,849 |
| Humalog Kwikpen U-100Insulin Lispro | 115 | $20,994 |
| TradjentaLinagliptin | 16 | $19,826 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 198 | $17,575 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 13 | $14,291 |
| XareltoRivaroxaban | 11 | $12,353 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 158 | $11,670 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $150 | $474,140375 claims |
| Novo NordiskOzempic | $837 | $362,133352 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humulin N | $449 | $197,442167 claims |
| AmgenProlia | $138 | $102,97860 claims |
| AstraZenecaFarxiga | $78 | $42,03139 claims |
| BayerKerendia | $721 | $25,84931 claims |
| AbbVieSynthroid | $22 | $1,88828 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Pasadena
- Jerrold OlefskySan Diego$26.5M
- Mark ChristiansenWalnut Creek$22.9M
- Timothy BaileyEscondido$22.3M
- Stanley HsiaLos Angeles$19.8M
- Juan FriasSan Diego$14.1M
- Paul NorwoodFresno$6.2M
- Athena Philis-Tsimikasla Jolla$6M
- David AhnNewport Beach$5.8M
- Shlomo MelmedLos Angeles$3.3M
- Leila ChaychiSan Carlos$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.